Latest Biologicals News

Murray Cod Australia Limited reports a profitable FY25 with a significant biomass increase and completes a $17 million capital raise to fund infrastructure and market expansion ahead of a commercial inflection in FY26.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

New Zealand King Salmon reported a $20.8 million net loss for the half year ending July 2025, driven by biological setbacks and reduced harvests. Despite this, the company maintains a strong balance sheet and is advancing its Blue Endeavour pilot farm and growth initiatives.

New Zealand King Salmon Investments Limited reported a significant interim loss driven by biological asset valuation pressures and operational costs, while announcing a strategic $8.14 million property purchase.

New Zealand King Salmon reports a $20.8 million net loss for the half-year ending July 2025, driven by biological asset write-downs, while maintaining EBITDA guidance and advancing key growth initiatives.

Murray Cod Australia Ltd reports a landmark FY25 profit turnaround driven by record biomass growth and infrastructure expansion, setting the stage for a commercial inflection in FY26.

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

dorsaVi has achieved a major engineering milestone by validating its RRAM-powered Reflex Platform, delivering neural reflex decisions in under one microsecond with ultra-low energy consumption. This breakthrough paves the way for next-generation robotics, prosthetics, and wearable devices that require rapid, energy-efficient reflex actions.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.